Candel Therapeutics
CADL
25 hedge funds and large institutions have $19.1M invested in Candel Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
9% more funds holding
Funds holding: 23 → 25 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.07% less ownership
Funds ownership: 22.12% → 21.05% (-1.1%)
75% less capital inflows, than outflows
Capital inflows: $306K | Capital outflows: $1.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$182K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$57.1K |
| 3 |
Millennium Management
New York
|
+$50.3K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$9.9K |
| 5 |
Morgan Stanley
New York
|
+$2.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.15M |
| 2 |
Goldman Sachs
New York
|
-$33K |
| 3 |
BlackRock
New York
|
-$14.9K |
| 4 |
Point72 Hong Kong
Hong Kong
|
-$2K |
| 5 |
Citigroup
New York
|
-$322 |
CADL Hedge Fund Activity: Q3 2022 in Review
25 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q3 2022, worth a combined $19.1M — down 7.1% from $20.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CADL positions and 2 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $182K. The largest seller was Point72 Asset Management, cutting an estimated $1.15M.
- 25 institutional investors held Candel Therapeutics (CADL) as of Q3 2022, up from 23 in Q2 2022.
- Funds reported $19.1M of Candel Therapeutics stock for Q3 2022, down 7.1% quarter-over-quarter.
- 4 funds opened new Candel Therapeutics positions in Q3 2022 and 2 closed out, a net change of +2 holders.
- The largest Candel Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $182K added.
- The largest Candel Therapeutics seller in Q3 2022 was Point72 Asset Management, an estimated $1.15M sold.
Based on aggregated 13F filings for Q3 2022.